233 results on '"Oscier, D G"'
Search Results
2. Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial
3. Longitudinal copy number, whole exome and targeted deep sequencing of ‘good risk’ IGHV-mutated CLL patients with progressive disease
4. Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage
5. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia
6. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL
7. Rapid amplification of immunoglobulin heavy chain switch (IGHS) translocation breakpoints using long-distance inverse PCR
8. P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12
9. Proteomic analysis of the cell-surface membrane in chronic lymphocytic leukemia: identification of two novel proteins, BCNP1 and MIG2B
10. Pharmacogenetic analysis of CYP2B6 in the LRF CLL4 trial: the *6 allelic variant is associated with inferior efficacy following fludarabine plus cyclophosphamide: 39
11. Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia
12. The significance of deletion architecture, ATM mutational status and genomic complexity in 11q deleted CLL: 29
13. Mutations in SF3B1, but not NOTCH1, are independently associated with survival in the UK CLL4 trial: 27
14. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations
15. Final response assessment of the CLL208 trial: an open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL).: 43
16. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease
17. Predicting clinical outcome in early stage chronic lymphocytic leukaemia (CLL): A multi-centre study of 1153 patients: 39
18. Male preponderance in chronic lymphocytic leukemia utilizing IGHV 1-69
19. Utility of early screening for JAK2 V617F mutation in patients with erythrocytosis or thrombocytosis in a District General Hospital: 235
20. HOX genes are a major target for epigenetic mis-regulation in adult and childhood leukaemia: 236
21. Guidelines on the management of Waldenström macroglobulinaemia
22. Novel technique to facilitate the rapid identification of CLL patients utilising the VH3-21 gene
23. Identification of a novel gene, GEMS, that is fused to FGFR1 in the 8p11 myeloproliferative syndrome
24. THE OPTIMAL MANAGEMENT OF POLYCYTHAEMIA VERA
25. THE MANAGEMENT OF 'LOW-RISK' AND 'INTERMEDIATE-RISK' PATIENTS WITH PRIMARY THROMBOCYTHAEMIA
26. Association of myelodysplastic changes with purine analogues
27. Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12
28. Trisomy 12 and structural abnormalities of 13q14 occurring in the same clone in chronic lymphocytic leukaemia
29. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia
30. Karyotypic evolution in a granulocytic sarcoma developing in a myeloproliferative disorder with a novel (3;4) translocation
31. Immunoreactive Calcitonin In Leukaemia
32. Pyogenic Abscesses In The Myelodysplastic Syndrome
33. Angiodysplasia of the Colon in Patients with Hemostatic Defects: Risk of Secondary Hemorrhage After Electrocoagulation Treatment.
34. Treatment of acute myeloid leukemia in the elderly: a clinical dilemma.
35. The myelodysplastic syndrome--a practical guide.
36. Peripheral blood stem cell autografting.
37. Autoimmune Haemolysis in Patients with B-CLL Treated with Chlorodeoxyadenosine (CDA).
38. Cellular/Cytogenetic Events in CLL.
39. Reciprocal translocation between chromosomes 8 and 9 in atypical chronic myeloid leukaemia.
40. Atypical chronic myeloid leukaemia, a distinct clinical entitity related to the myelodysplastic syndrome?
41. Cytogenetic studies in splenic lymphoma with villous lymphocytes.
42. Clonality of cell populations in refractory anaemia using combined approach of gene loss and X-linked restriction fragment length polymorphism-methylation analyses.
43. Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia.
44. Prognostic factors in stage AO B-cell chronic lymphocytic leukaemia.
45. The application of X-chromosome gene probes to the diagnosis of myeloproliferative disease.
46. TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKAEMIA WITH LOW DOSE ETOPOSIDE.
47. Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival.
48. Long survival in B-CLL correlates with surface IgM K phenotype.
49. Peripheral blood stem cell autografts in the treatment of lymphoid malignancies: initial experience in three patients.
50. Detection of cells of megakaryocyte lineage in haematological malignancies by immuno-alkaline phosphatase labelling cell smears with a panel of monoclonal antibodies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.